Six months ago, our 501 (c)(4) partner organization Unleash Prosperity Now, launched a project called Most Favored Patient that was designed to steer Trump away from dangerous drug price controls. Instead, we designed a plan that would force other free-loading nations of Europe and Asia to stop free-riding on American pharmaceutical innovation.
The reflexive solution would be for the US to adopt similar price controls, which Trump was threatening, but this would’ve stunted the race for the cure for terrible diseases.
So we congratulate President Trump and US Trade Representative Jamieson Greer for accomplishing what we proposed as the best solution to this thorny problem: negotiate into trade agreements with other rich countries provisions that require them to pay more for innovative prescription drugs. They have done just that with the UK:
Pursuant to the terms of the pharmaceutical pricing agreement in principle announced today, the United Kingdom will reverse the decade-long trend of declining National Health Service (NHS) expenditures on innovative, life-saving medicines, and increase the net price it pays for new medicines by 25%. Furthermore, the United Kingdom will ensure that higher prices for new medicines are not materially eroded by a demand for portfolio-wide concessions under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) or other rebate schemes. In fact, the United Kingdom has committed that the repayment rate owed by companies under the current VPAG scheme will decrease to 15% in 2026 and remain at or below that level for the duration of the scheme...
In exchange for these and other commitments, the United States has agreed to exempt U.K.-origin pharmaceuticals, pharmaceutical ingredients, and medical technology from Section 232 tariffs and will refrain from targeting U.K. pharmaceutical pricing practices in any future Section 301 investigation for the duration of President Trump's term. Further, the United States will work to ensure that U.K. citizens have access to the latest pharmaceutical breakthroughs.